Plinabulin + G-CSF
Prevention of Chemotherapy-Induced Neutropenia (CIN)
Key Facts
About BeyondSpring
BeyondSpring is a NASDAQ-listed biotech focused on developing plinabulin, a novel immunomodulating microtubule-binding agent, for oncology. Its primary objectives are securing approval for plinabulin to prevent chemotherapy-induced neutropenia (CIN) and demonstrating its efficacy as a combination therapy in non-small cell lung cancer (NSCLC). The company's strategy leverages a dual-mechanism platform to differentiate from standard care and targets high-value markets in the US and China. Despite a prior FDA Complete Response Letter for CIN, BeyondSpring continues to generate supportive clinical data, particularly from its Phase 3 DUBLIN-3 trial in NSCLC, to build a compelling case for global registration.
View full company profile